BioLineRx (BLRX) Return on Sales (2023 - 2025)
Historic Return on Sales for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to 4.46%.
- BioLineRx's Return on Sales fell 37000.0% to 4.46% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.09%, marking a year-over-year increase of 9000.0%. This contributed to the annual value of 0.67% for FY2024, which is 92300.0% up from last year.
- According to the latest figures from Q3 2025, BioLineRx's Return on Sales is 4.46%, which was down 37000.0% from 6.67% recorded in Q2 2025.
- In the past 5 years, BioLineRx's Return on Sales registered a high of 20.92% during Q4 2023, and its lowest value of 13.76% during Q3 2023.
- In the last 3 years, BioLineRx's Return on Sales had a median value of 2.62% in 2024 and averaged 2.32%.
- Examining YoY changes over the last 5 years, BioLineRx's Return on Sales showed a top increase of 130000bps in 2024 and a maximum decrease of -216000bps in 2024.
- Over the past 3 years, BioLineRx's Return on Sales (Quarter) stood at 20.92% in 2023, then plummeted by -103bps to 0.68% in 2024, then crashed by -560bps to 4.46% in 2025.
- Its Return on Sales was 4.46% in Q3 2025, compared to 6.67% in Q2 2025 and 7.73% in Q1 2025.